The effect of magnesium supplementation in increasing doses on the control of ty

[Guest guest]

Here is the url to the whole article

http://care.diabetesjournals.org/cgi/reprint/21/5/682.pdf which says " Several

studies have suggested

an association between magnesium depletion and insulin resistance and/or

reduction of insulin secretion in these cases.Our purpose was to evaluate

control in

patients with Type 2 Diabetes. "

Read also http://www.imva.info/diabetes.shtml

http://www.imva.info/diabetes_magnesium.shtml

http://www.imva.info/diabetesneuropathy.shtml

" Magnesium is necessary for the

 production, function & transport of insulin "

However, I would like to say that I do not have diabetes, though I

do have peripheral neuropathy. And transdermal magnesium has proved that it

does indeed cure it. Due to circumstances, I had to stop using the transderamal

magnesium for 3 months and the neuropathy got considerably worse. I have just

started using it again thank heavens, and already it is making a difference

again. I will never do that again.

blessings

Shan

 

The effect of magnesium supplementation in increasing doses on the control of

type 2 diabetes.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve & db=pubmed &

dopt=Abstract & list_uids=9589224 & itool=iconfft & query_hl=34 & itool=pubmed_docsum

de Lordes Lima M, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Cangucu V.

Department of Medicine, Bahia Federal University Medical School, Brazil.

 

OBJECTIVE:

 

Hypomagnesemia occurs in 25-38% of patients with type 2 diabetes. Several

studies have suggested an association between magnesium (Mg) depletion and

insulin resistance and/or reduction of insulin secretion in these cases. Our

purpose

was to evaluate if Mg supplementation (as magnesium oxide [MgO]) would

improve metabolic control in patients with type 2 diabetes.

 

RESEARCH DESIGN AND METHODS:

 

We studied 128 patients with type 2 diabetes (32 men, 96 women, aged 30-69

years), treated by diet or diet plus oral antidiabetic drugs, in the Bahia

Federal University Hospital, Brazil. Patients at risk for hypomagnesemia or with

reduced renal function were excluded. This study was a clinical randomized

double-blind placebo-controlled trial. Patients received either placebo, 20.7

mmol

MgO, or 41.4 mmol MgO daily (elementary Mg) for 30 days. Mg concentrations

were measured in plasma, in mononuclear cells, and in 24-h urine samples.

Fasting

blood glucose, HbA1, and fructosamine were used as parameters of metabolic

control.

 

RESULTS:

 

Of the patients, 47.7% had low plasma Mg, and 31.1% had low intramononuclear

Mg levels. Intracellular Mg in patients with diabetes was significantly lower

than in the normal population (62 blood donors; 1.4 +/- 0.6 vs. 1.7 +/- 0.6

micrograms/mg of total proteins). No correlation was found between plasma and

intracellular Mg concentrations (r = -0.179; P = 0.15) or between Mg

concentrations and glycemic control (r = -0.165; P = 0.12). Intracellular Mg

levels were

lower in patients with peripheral neuropathy than in those without (1.2 +/-

0.5 vs. 1.5 +/- 0.6 micrograms/mg). Similar findings were observed in patients

with coronary disease (1.0 +/- 0.5 vs. 1.5 +/- 0.6 micrograms/mg). In the

placebo and in the 20.7 mmol Mg groups, neither a change in plasma and

intracellular levels nor an improvement in glycemic control were observed.

Replacement

with 41.4 mmol Mg tended to increase plasma, cellular, and urine Mg and caused a

significant fall (4.1 +/- 0.8 to 3.8 +/- 0.7 mmol/l) in fructosamine (normal,

1.87-2.87 mmol/l).

 

CONCLUSIONS:

 

Mg depletion is common in poorly controlled patients with type 2 diabetes,

especially in those with neuropathy or coronary disease. More prolonged use of

Mg in doses that are higher than usual is needed to establish its routine or

selective administration in patients with type 2 diabetes to improve control or

prevent chronic complications.